Angiotensin-II Blockade in Mitral Regurgitation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905'
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients:
- 18 years old or older, with
- Mitral regurgitation on the basis of Color flow imaging
- Due to organic disease of the mitral valve on the basis of two-dimensional echocardiography
- Isolated (no valve disease other than functional tricuspid regurgitation on the basis of Doppler-Echocardiography)
- Pure (no mitral stenosis by Doppler echocardiography)
- Quantifiable by Doppler-Echocardiographic methods
- Of more than mild degree, defined as regurgitant volume * 30 mL/beat
- Occurring on native valves
- With Two-dimensional echocardiographic imaging allowing assessment of LV remodeling, and
- Asymptomatic (or mildly symptomatic but not considered as candidates for immediate surgery by their attending physician).
Exclusion Criteria:
- Associated aortic valve disease (more than trace aortic regurgitation by color flow imaging or mean gradient *25 mmHg)
- Associated mitral stenosis (mean gradient* 5 mmHg, valve area < 1.5 cm2)
- Associated congenital or pericardial diseases on the basis of Doppler echocardiography
- Intolerance to either AII blockers or Angiotensin converting enzyme inhibitors
- Intolerance to iodine contrast material
- Intolerance to intravenous echographic contrast agents
- Renal failure with creatinine * 2 mg/dl
- Blood pressure below 100 mmHg
- Known renal artery stenosis
- Ongoing therapy with hydralazine, calcium-entry blocking drugs or angiotensin converting enzyme inhibitors
- Known severe comorbidity such as liver disease, malignancy
- Pregnancy (A negative pregnancy test and effective contraceptive methods are required prior to enrollment of females of childbearing potential (not post-menopausal or surgically sterilized)), and
- Patients considered as requiring mitral valve surgery by their attending physician or with previous valve repair or replacement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: 2
Placebo
|
Placebo
|
|
EXPERIMENTAL: 1
Atacand treatment.
|
Maximum vasodilation.
Other Names:
maximum vasodilation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Tolerance of the medication.
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Decrease of severity of mitral regurgitation.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Maurice E. Sarano, M.D., Mayo Clinic Foundation
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1129-98
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.